A	B	C	D	E	F	G	H	I
1	Main
2		Brand	Generic	Indication	MOA	Phase	Active?	Company	Notes
3		SEP-363856	ulotaront	Schizophrenia	TAAR agonist	III	YES	4506 JP	Phase II n=245, 50mg, 75mg or PBO. -17.2 points vs -9.7 points at 4 weeks.
4								SAGE
5			tedatioxetine					TAK/LUN
6		TAK-041/NBI-846		Depression	GPR139 agonist	II	YES
7		TAK-653/NBI-845		Depression	AMPA agonist
8			amantadine
9		MK-1942		TRD			YES	MRK
10		CVL-231	emraclidine	Schizophrenia	M4 PAM	II	YES	CERE
11		NBI-1117568		Schizophrenia	M4 PAM	II	YES	NBIX
12		MK-8189		Schizophrenia	PDE10A inhibitor	II	YES	MRK
13		RP5063	brilaroxazine	Schizophrenia	D2 partial agonist	III	YES	Reviva Pharmaceuticals
14		KarXT	xanomeline, trospium	Schizophrenia	M4 PAM	III	YES	KRTX
15		CPL500036		Schizophrenia	PDE10A inhibitor	II	YES	Celon Pharma SA
16		Falkieri	esketamine	Bipolar Depression	NMDA		YES	Celon Pharma SA
17		BI 425809		Schizophrenia	GlyT1 inhibitor	II	YES	Boehringer Ingelheim
18		TV-44749	olanzapine	Schizophrenia	D2 antagonist	III	YES	TEVA
19		TPN672		Schizophrenia	D2 antagonist	I	YES	Jiangsu Kanion
20			agomelatine
21		TAK-831/NBI-1065844	luvadaxistat	CIS Schizophrenia	DAAO inhibitor			TAK/NBIX
22		RL-007		CIS Schizophrenia	GABA/nicotinic	I	YES	Recognify
23		HS-10380						Jiangsu Hansoh
24		LYN-005	risperidone	Schizophrenia	D2 antagonist	I	YES	Lyndra Therapeutics
25		JX11502MA		Schizophrenia				Zhejiang Jingxin
26		LY03010	paliperidone palmitate	Schizophrenia
27		vabicaserin
28		PF-02545920
29		RG1678
30		MK-0249
31		encenicline
32		LY404039
33		CX516
34		SR48692
35		SR142801
36		SR141716
37		L-745870
38		SCH39166
39		M100907
40		TAK-063